FDA Concern Over Drug Production Process At India's Cadila

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

(Reuters) - India's Cadila Healthcare Ltd is responding to certain observations the U.S. Food and Drug Administration (FDA) made after conducting a "product specific" inspection of its Moraiya manufacturing plant, a company spokeswoman said on Thursday.

Sources with direct knowledge told Reuters earlier that the FDA expressed concerns over the manufacturing process of at least one product at Cadila's Moraiya facility in the western Indian state of Gujarat.

Help employers find you! Check out all the jobs and post your resume.

Back to news